Heart transplant patients may get safer Anti-Rejection option
NCT ID NCT04477629
First seen Jan 07, 2026 · Last updated Jun 15, 2026 · Updated 26 times
Summary
This study tests whether belatacept, an anti-rejection medication, is safe for adults who have just received a new heart. About 12 participants will receive the drug and be monitored for serious complications like rejection, infection, or organ failure. The goal is to find a better way to prevent the body from attacking the new heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Columbia University
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.